Welcome to this week's Chutes and Ladders, our roundup of hirings, firings and retirings throughout the industry. Please send the good word--or the bad--from your shop to Eric Sagonowsky (email) or Angus Liu (email), and we will feature it here at the end of each week.
Allergan International’s former head Paul Navarre to lead Nestlé Skin Health
Nestlé Skin Health
Paul Navarre becomes new CEO.
Nestlé, one of the world’s largest food companies, has been boosting its businesses in health and medicine, and its most recent move toward that direction is the recruitment of former Allergan ($AGN) exec Paul Navarre as the new CEO of its dermatology branch. Navarre has spent 10 years at Allergan and was most recently the president of Allergan’s international business outside the U.S. Prior to that, he spent 15 years with Procter & Gamble ($PG), being involved in both consumer goods and healthcare. Humberto Antunes, the company’s current CEO, “has decided to give a new direction to his career” and will leave the company at the end of October, according to a release sent out by the company. Nestlé Skin Health was formerly known as Galderma, a JV co-owned by Nestlé and L’Oréal, and became a wholly owned subsidiary of Nestlé in 2014. FiercePharma
Boston Scientific hires veteran cardiologist Prof. Ian Meredith as EVP and CMO
Prof. Ian Meredith will join as EVP and global CMO.
Prof. Ian Meredith, a professor of medicine and cardiology at Monash University in Melbourne, Australia and the head of its CV research, will join medical device giant Boston Scientific ($BSX) as its executive vice president and global chief medical officer next January. He is taking the baton from Dr. Keith Dawkins, who has announced his intention to retire after nine years with the company. Prof. Meredith brings with him more than 25 years of experience as a clinical and interventional cardiologist. His researches are focused on devices for the treatment of coronary artery and structural heart disease, and he has been an adviser to the company for many years in that field. “His strong relationships within the global research and clinical community and his track record applying novel technologies to advance science and care for patients make him ideally suited to drive innovation and succeed Keith in this role,” said Mike Mahoney, chairman and CEO of Boston Scientific. Release
Enrico Bastianelli to step down as CEO of Bone Therapeutics
Enrico Bastianelli is leaving the company.
After 10 years with Bone Therapeutics, Enrico Bastianelli recently decided to quit his role as CEO of the company for personal reasons, leaving current chief business officer Thomas Lienard, who joined the company less than a year ago, as Interim CEO. Pior to joining Bone Therapeutics, Lienard had worked at Lundbeck and Eli Lilly ($LLY). During Bastianelli’s reign, Bone Therapeutics achieved a successful IPO in 2015, raising €37 million. He also helped Preob and Allob--two of the company’s first-in-class drugs--through development process. FierceBiotech
> Millendo Therapeutics of Ann Arbor, MI, has named John Kirk as VP of regulatory affairs, Naidong Ye, as VP of chemistry, manufacturing and controls, and Jennifer Minai-Azary as VP of finance. Release
> Rock Health named Bill Evans as its managing director. Evans joins after 13 years at Genentech and its parent company Roche. Release
> Carl Zeiss Meditec, the Medical Technology Business Group of Zeiss, appoints Dr. Steven C. Schallhorn as Chief Medical Officer for global ophthalmic devices. Release
> Siga Technologies taps Dr. Phil Gomez as new CEO. Release
> Osage University Partners, a venture capital fund that invests in university startups in fields including life sciences, announces the promotion of Matt Cohen to Principal. Release